2 Strong Medical Marijuana Plays Show Share Price Appreciation

Summary

• GW Pharmaceuticals benefiting from competitors' setbacks.
• Emerald Bioscience stock price had accelerated on good news.
• GW Pharmaceuticals expecting news from FDA on TSC (tuberous sclerosis complex) shortly.
• Growing realisation of potential medical benefits from cannabinoids.

GW Pharmaceuticals (GWPH) and Emerald Bioscience (OTCQB:EMBI) are two medical marijuana stocks I have been recommending for some time. My last article on them was in February. Readers can refer to the comprehensive details of their drug development plans there.

Since my article, other factors have fallen in favour of these two cannabinoid drug development companies. Their stock prices have risen further as a result. In the case of Emerald Bioscience, the stock price is subject to sharp movements.

In general, specialty drug development from patented cannabinoids seems to me to be a far better investment opportunity than the overcrowded and somewhat commoditised retail cannabis market.
Read More